Fig. 3From: Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trialCost-effectiveness plane for the primary cost-effectiveness analysis showing bootstrapped replications of mean incremental costs and quality-adjusted life year (QALY) gain and the willingness-to-pay (WTP) threshold of £20,000/QALYBack to article page